Skip to main content

Fate Therapeutics Inc

FATE
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001434316

In the last 90 days, Fate Therapeutics Inc insiders filed 0 open-market purchases and 2 sales; 156 institutions reported holding it in 13F filings for Q2 2026, worth $193.2M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Fate Therapeutics Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
2 filings
2 insiders, $203.5K in total
Insiders trading
2
Net value
−$203.5K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Fate Therapeutics Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Fate Therapeutics Inc
NameTitleLast reported holdingLast filingFilings, past year
Tahl CindySee Remarks589,355Aug 5, 20265
Valamehr BahramPresident and CEO591,815Aug 5, 20264
Redmile Group, LLCDirector, 10% Owner12,884,277IndirectJun 15, 20262
Green JeremyDirector, 10% Owner12,884,277IndirectJun 15, 20262
Rastetter William HDirector36,331Jun 15, 20262
Epstein Robert SDirector36,331Jun 15, 20262
Abernethy MattDirector–Jun 15, 20261
Agarwal ShefaliDirector10,490Jun 15, 20261
Lee Michael StewartDirector11,331Jun 15, 20261
Hamill LauraDirector–Jun 15, 20261
Jooss KarinDirector9,848Jun 15, 20261
Xu YuanDirector8,669Jun 15, 20261
RedCo II Master Fund, L.P.Director, 10% Owner12,884,277IndirectApr 23, 20261
Adawi KamalChief Financial Officer100,000Jan 16, 20262
Mendlein JohnDirector311,231May 30, 20250
Mozaffarian NeelufarDirector–May 30, 20250
Bressi Jerome CharlesSee Remarks335,203Jan 16, 20250
Coughlin TimothyDirector9,892Jun 11, 20240
Dulac Edward J IIIChief Financial Officer101,479Mar 5, 20240
Wolchko J ScottPresident and CEO371,248Feb 2, 20240
Powl Brian T.Chief Commercial Officer41,146Jul 6, 20230
Hershberg RobertDirector10,659Jun 7, 20230
Chu Yu-WayeChief Medical Officer140,676Apr 19, 20230
Plavsic MarkChief Technical Officer123,705Jan 11, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 2, 2021 (view filing)Jul 11 dayTahl CindyGeneral Counsel and SecretarySSale−55.5K$85.24−$4.73M−33.9%108.0K afterFrom original11 lots
Jul 26, 2021 (view filing)Jul 22-234 daysWolchko J ScottPresident and CEOSSale−60.0K$85.66−$5.14M−13.2%393.8K after4 lots
Aug 20, 2021 (view filing)Aug 191 dayDulac Edward J IIIChief Financial OfficerSSale−3.47K$88.26−$306.6K−6.0%54.5K after3 lots
Aug 20, 2021 (view filing)Aug 191 dayWolchko J ScottPresident and CEOSSale−20.0K$88.01−$1.76M−4.8%393.8K after
Sep 14, 2021 (view filing)Sep 131 dayValamehr BahramChief Development OfficerSSale−25.0K$66.29−$1.66M−20.7%95.7K after3 lots
Sep 30, 2021 (view filing)Sep 282 daysDulac Edward J IIIChief Financial OfficerSSale−19.5K$62.53−$1.22M−27.1%52.4K after
Oct 4, 2021 (view filing)Oct 13 daysTahl CindyGeneral Counsel and SecretarySSale−50.0K$58.83−$2.94M−31.6%108.0K after3 lots
Oct 25, 2021 (view filing)Oct 21-224 daysWolchko J ScottPresident and CEOSSale−60.0K$59.55−$3.57M−13.2%393.8K after3 lots
Nov 22, 2021 (view filing)Nov 184 daysWolchko J ScottPresident and CEOSSale−20.0K$54.27−$1.09M−4.8%393.8K after
Dec 13, 2021 (view filing)Dec 103 daysChu Yu-WayeSenior VP Clinical DevelopmentSSale−7.50K$51.46−$385.9K−5.6%125.8K after7 lots
Dec 14, 2021 (view filing)Dec 131 dayValamehr BahramChief R&D OfficerSSale−25.0K$47.66−$1.19M−13.8%156.7K after5 lots
Dec 21, 2021 (view filing)Dec 201 dayDulac Edward J IIIChief Financial OfficerSSale−16.0K$60.00−$958.6K−12.6%110.4K after
Jan 4, 2022 (view filing)Jan 31 dayTahl CindyGeneral Counsel and SecretarySSale−50.0K$59.34−$2.97M−22.8%169.0K after4 lots
Jan 12, 2022 (view filing)Jan 102 daysValamehr BahramChief R&D OfficerSSale−5.60K$46.38−$259.6K−3.6%151.1K after2 lots
Jan 12, 2022 (view filing)Jan 102 daysTahl CindyGeneral Counsel and SecretarySSale−7.74K$46.43−$359.3K−4.6%161.3K after2 lots
Jan 12, 2022 (view filing)Jan 102 daysWolchko J ScottPresident and CEOSSale−34.2K$46.86−$1.60M−7.1%446.1K after3 lots
Jan 13, 2022 (view filing)Jan 112 daysChu Yu-WayeSenior VP Clinical DevelopmentSSale−3.96K$48.51−$192.3K−3.2%121.8K after2 lots
Jan 13, 2022 (view filing)Jan 112 daysDulac Edward J IIIChief Financial OfficerSSale−1.77K$48.45−$85.8K−1.6%108.6K after2 lots
Jan 13, 2022 (view filing)Jan 112 daysValamehr BahramChief R&D OfficerSSale−4.57K$48.50−$221.7K−3.0%146.5K after2 lots
Jan 13, 2022 (view filing)Jan 112 daysTahl CindyGeneral Counsel and SecretarySSale−5.42K$48.53−$263.0K−3.4%155.8K after2 lots
Jan 13, 2022 (view filing)Jan 112 daysWolchko J ScottPresident and CEOSSale−14.6K$48.68−$709.0K−3.3%431.5K after2 lots
Jan 24, 2022 (view filing)Jan 20-214 daysWolchko J ScottPresident and CEOSSale−40.0K$39.66−$1.59M−8.5%431.5K afterFrom original2 lots
Mar 11, 2022 (view filing)Mar 101 dayMendlein JohnDirectorSSale−31.6K$35.02−$1.11M−16.5%159.5K after2 lots
Mar 15, 2022 (view filing)Mar 141 dayValamehr BahramChief R&D OfficerSSale−25.0K$31.07−$776.7K−12.2%179.8K after5 lots
Apr 4, 2022 (view filing)Apr 13 daysTahl CindyGeneral Counsel and SecretarySSale−25.0K$38.85−$971.3K−11.7%189.2K after
Apr 21, 2022 (view filing)Apr 192 daysChu Yu-WayeChief Medical OfficerSSale−4.06K$35.37−$143.7K−2.6%151.0K after
Apr 25, 2022 (view filing)Apr 21-224 daysWolchko J ScottPresident and CEOSSale−40.0K$34.89−$1.40M−8.5%431.5K after6 lots
Jun 2, 2022 (view filing)Jun 11 dayTahl CindyGeneral Counsel and SecretarySSale−25.0K$22.96−$574.0K−11.7%189.2K after
Jun 6, 2022 (view filing)Jun 33 daysCoughlin TimothyDirectorSSale−1.44K$22.81−$32.8K−2.4%57.6K after
Jun 6, 2022 (view filing)Jun 33 daysHershberg RobertDirectorSSale−672$22.75−$15.3K−25.1%2.01K after
Jun 6, 2022 (view filing)Jun 33 daysJooss KarinDirectorSSale−1.48K$22.82−$33.8K−55.3%1.20K after
Jun 6, 2022 (view filing)Jun 33 daysMendlein JohnDirectorSSale−1.36K$22.79−$31.1K−0.9%158.1K after
Jun 8, 2022 (view filing)Jun 35 daysAgarwal ShefaliDirectorSSale0–$00.0%2.68K afterAmended
Jun 8, 2022 (view filing)Jun 71 dayAgarwal ShefaliDirectorSSale−841$21.89−$18.4K−31.4%1.84K after
Jul 6, 2022 (view filing)Jul 51 dayPlavsic MarkChief Technical OfficerSSale−3.72K$24.61−$91.5K−2.8%127.1K after
Jul 7, 2022 (view filing)Jul 61 dayValamehr BahramChief R&D OfficerSSale−7.84K$30.07−$235.8K−4.2%179.8K after
Jul 8, 2022 (view filing)Jul 71 dayValamehr BahramChief R&D OfficerSSale−17.2K$30.23−$518.7K−8.7%179.8K after
Jul 25, 2022 (view filing)Jul 21-224 daysWolchko J ScottPresident and CEOSSale−36.2K$32.74−$1.19M−7.7%431.5K after5 lots
Aug 19, 2022 (view filing)Aug 181 dayDulac Edward J IIIChief Financial OfficerSSale−5.13K$29.81−$153.1K−3.6%136.8K after2 lots
Jan 11, 2023 (view filing)Jan 101 dayChu Yu-WayeChief Medical OfficerSSale−7.83K$5.24−$41.0K−5.2%143.2K after
Jan 11, 2023 (view filing)Jan 101 dayDulac Edward J IIIChief Financial OfficerSSale−7.33K$5.24−$38.4K−5.4%129.5K after
Jan 11, 2023 (view filing)Jan 101 dayPlavsic MarkChief Technical OfficerSSale−3.42K$5.24−$17.9K−2.7%123.7K after
Jan 11, 2023 (view filing)Jan 101 dayTahl CindyGeneral Counsel and SecretarySSale−11.6K$5.24−$60.5K−6.1%177.6K after
Jan 11, 2023 (view filing)Jan 101 dayValamehr BahramChief R&D OfficerSSale−10.9K$5.24−$57.2K−6.1%168.9K after
Jan 11, 2023 (view filing)Jan 101 dayWolchko J ScottPresident and CEOSSale−45.9K$5.24−$240.6K−10.6%385.6K after
Jan 13, 2023 (view filing)Jan 11-132 daysMendlein JohnDirectorPPurchase+124.7K$5.60+$698.1K+78.9%282.8K after2 lots
Apr 17, 2023 (view filing)9:30 PM ETApr 143 daysRedmile Group, LLC and 1 otherDirector, 10% OwnerSSale−302.3K$5.84−$1.77M−2.3%12.8M after
Apr 17, 2023 (view filing)9:30 PM ETApr 143 daysRedmile Group, LLC and 1 otherDirector, 10% OwnerPPurchase+25.7K$6.00+$154.2K+0.2%12.9M after
Apr 19, 2023 (view filing)Apr 181 dayChu Yu-WayeChief Medical OfficerSSale−2.53K$6.57−$16.6K−1.8%140.7K after2 lots10b5-1
Apr 21, 2023 (view filing)9:55 PM ETApr 20-211 dayRedmile Group, LLC and 1 otherDirector, 10% OwnerPPurchase+276.6K$6.17+$1.71M+2.2%13.1M after2 lots